Who Paid My Doc
Brad Baltz
Hematology & Oncology Little Rock, AR Medical Doctor
NPI 1164484614 CMS profile 97819
1300 Centerview Dr, Little Rock, AR 72211
General payments
$25,054
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$81,146
Through program year 2025, Brad Baltz of Little Rock, AR is reported in the CMS Open Payments database as having received $25,054 across 1,572 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $81,146 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 83rd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,407 | 213 | |
| 2024 | General | $3,911 | 227 | |
| 2023 | General | $3,445 | 214 | |
| 2022 | General | $3,052 | 206 | |
| 2021 | General | $2,978 | 197 | |
| 2020 | General | $2,873 | 198 | |
| 2019 | General | $4,389 | 317 |
Beside peers
- Brad Baltz
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Brad Baltz were reported at $4,407. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Brad Baltz | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,389 | $529 | $121–$2,516 | $163 |
| 2020 | $2,873 | $339 | $82–$2,213 | $114 |
| 2021 | $2,978 | $263 | $49–$1,965 | $132 |
| 2022 | $3,052 | $416 | $103–$2,395 | $149 |
| 2023 | $3,445 | $542 | $125–$2,646 | $160 |
| 2024 | $3,911 | $692 | $141–$3,008 | $164 |
| 2025 | $4,407 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 133 billing codesPaid by Medicare
$2,247,062
Medicare patients
1,018
Services billed
102,342
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 56% | |
| Ischemic heart disease | 40% | |
| Cancer | 36% | |
| Diabetes | 35% | |
| Chronic kidney disease | 32% | |
| Atrial fibrillation | 26% | |
| Depression | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, luspatercept-aamt, 0.25 mg J0896 | Office | 11 | 11,500 | $366,364 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 27 | 14,200 | $33,816 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 17 | 823 | $71 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 12 | 146 | $34 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,572 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hematology & Oncology in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.